Medtronic (MDT) Depreciation & Amortization (CF) (2014 - 2026)

Medtronic (MDT) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $716.0 million in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 14.76% year-over-year to $716.0 million; the trailing twelve-month figure through Apr 2026 stood at $3.0 billion (up 3.39% YoY), and the FY2026 full-year result was $3.0 billion, up 3.39% from the prior year.
• Depreciation & Amortization (CF) declined to $716.0 million in Q2 2026, from $749.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $840.0 million in Q2 2025 to a low of $649.0 million in Q1 2024.
• A 5-year average of $695.7 million and a median of $677.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) grew 28.44% in 2025 and declined 14.76% in 2026, its largest moves.
• Tracing MDT's Depreciation & Amortization (CF) over 5 years: stood at $671.0 million in 2022, then gained by 0.15% to $672.0 million in 2023, then grew by 0.45% to $675.0 million in 2024, then gained by 10.37% to $745.0 million in 2025, then retreated by 3.89% to $716.0 million in 2026.
• Business Quant data shows MDT's Depreciation & Amortization (CF) at $716.0 million in Q2 2026, $749.0 million in Q1 2026, and $745.0 million in Q4 2025.